Liraglutide Formulations Compared for Bioequivalence in Healthy Volunteers

Liraglutide, a GLP-1 receptor agonist, is a widely used medication for type 2 diabetes and obesity. As drugs progress through development, formulations can change, necessitating rigorous testing to ensure consistency. This Phase 1 study specifically aimed to confirm the bioequivalence between a completed Phase 2 formulation and a planned Phase 3 formulation of liraglutide, ensuring that any changes in manufacturing or composition do not alter the drug's absorption or efficacy.

While specific numerical results for Area under the Curve (AUC) and maximum concentration (Cmax) were not detailed in the provided summary, the study's primary objective was to test for bioequivalence between the two liraglutide formulations. Bioequivalence is typically established if the 90% confidence intervals for the ratio of these pharmacokinetic parameters (test formulation vs. reference formulation) fall within a predefined range, commonly 80-125%. Secondary outcomes included AUC (0-infinity), tmax (time to maximum concentration), t½ (terminal half-life), and terminal elimination rate constant, alongside monitoring for adverse events. The successful demonstration of bioequivalence would indicate that the two formulations deliver the drug to the body in a comparable manner. The overarching goal of this study was to confirm that the planned Phase 3 liraglutide formulation was pharmacokinetically equivalent to the Phase 2 formulation, ensuring consistent drug exposure and safety.